![Heng Xie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Heng Xie worked as a Director at Beijing Biostar Pharmaceuticals Co. Ltd.
in 2022.
Prior to that, he obtained a doctorate degree from The University of Alabama at Birmingham in 1997.
Anciens postes connus de Heng Xie
Sociétés | Poste | Fin |
---|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
![]() Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 01/06/2022 |
Formation de Heng Xie
The University of Alabama at Birmingham | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
![]() Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Health Technology |